Back to Browse Journals » Drug Design, Development and Therapy » Volume 2

A safety-modified SV40 Tag developed for human cancer immunotherapy

Authors Stephanie S Tseng-Rogenski, Mohamed S Arredouani, June F Escara-Wilke, Yilin C Neeley, Michael J Imperiale et al

Published Date January 2008 Volume 2008:2 Pages 17—24

DOI

Published 8 January 2008

Stephanie S Tseng-Rogenski1, Mohamed S Arredouani2, June F Escara-Wilke1, Yilin C Neeley1, Michael J Imperiale3, Martin G Sanda1,2

1Department of Urology, School of Medicine, University of Michigan, Ann Arbor, MI, USA; 2Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 3Department of Microbiology and Immunology, School of Medicine, University of Michigan, Ann Arbor, MI, USA

Abstract: Simian virus 40 (SV40)-like DNA sequences have been found in a variety of human tumors, raising the possibility that strategies targeting SV40 may provide a potential avenue for immunotherapy directed against SV40 large T Antigen (Tag)-expressing tumors. We generated a recombinant vaccinia (vac-mTag) expressing mTag and herein assessed the ability of mTag to transform cells and to interact with anti-oncoproteins, as well as screened for the presence of potential HLA-A2.1-restricted epitopes within mTag. We found that transfection of cells with mTag did not lead to their transformation. Also, we demonstrated that mTag protein is degraded rapidly in cells. In addition, our work revealed that mTag did not physically interact with certain anti-oncoproteins. Finally, two potential HLA-A2.1-restricted functional epitopes within mTag sequence were identified. Our results show that mTag lacks the oncogenecity of full-length Tag and harbors potential HLA-A2.1-restricted immunogenic epitopes, hence suggesting the safety of vac-mTag for use in cancer immunotherapy.
Keywords: modified SV-40 T antigen, recombinant vaccinia, cancer immunotherapy

Download Article [PDF] 

Readers of this article also read:

Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies

Capolla S, Garrovo C, Zorzet S, Lorenzon A, Rampazzo E, Spretz R, Pozzato G, Núñez L, Tripodo C, Macor P, Biffi S

International Journal of Nanomedicine 2015, 10:4099-4109

Published Date: 22 June 2015

Chitosan–tripolyphosphate nanoparticles as Arrabidaea chica standardized extract carrier: synthesis, characterization, biocompatibility, and antiulcerogenic activity

Servat-Medina L, González-Gómez A, Reyes-Ortega F, Sousa IMO, Queiroz NCA, Zago PMW, Jorge MP, Monteiro KM, de Carvalho JE, San Román J, Foglio MA

International Journal of Nanomedicine 2015, 10:3897-3909

Published Date: 9 June 2015

Novel PLGA-based nanoparticles for the oral delivery of insulin

Malathi S, Nandhakumar P, Pandiyan V, Webster TJ, Balasubramanian S

International Journal of Nanomedicine 2015, 10:2207-2218

Published Date: 19 March 2015

Development of an oral push–pull osmotic pump of fenofibrate-loaded mesoporous silica nanoparticles

Zhao Z, Wu C, Zhao Y, Hao Y, Liu Y, Zhao W

International Journal of Nanomedicine 2015, 10:1691-1701

Published Date: 3 March 2015

Effect of nanofiber content on bone regeneration of silk fibroin/poly(ε-caprolactone) nano/microfibrous composite scaffolds

Kim BS, Park KE, Kim MH, You HK, Lee J, Park WH

International Journal of Nanomedicine 2015, 10:485-502

Published Date: 9 January 2015

The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia

Shao IH, Hou CP, Chen SM, Chen CL, Lin YH, Chang PL, Tsui KH

Clinical Interventions in Aging 2013, 8:431-432

Published Date: 16 April 2013

Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies

Kevin J Ruff, Dale P DeVore, Michael D Leu, Mark A Robinson

Clinical Interventions in Aging 2009, 4:235-240

Published Date: 18 May 2009